Clinical Trial

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-11-01; most recent amendment 2026-03-13.
Trial Details
NCT Number NCT05119179
Lead Sponsor The University of Texas Health Science Center, Houston
Collaborators: Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions PreDiabetes
Enrollment 300 participants
Start Date 2021-11-22
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-17